Psychopharmacological interventions in autism spectrum disorder

被引:69
作者
Accordino, Robert E. [1 ,2 ,3 ]
Kidd, Christen [4 ]
Politte, Laura C. [5 ]
Henry, Charles A. [6 ]
McDougle, Christopher J. [7 ]
机构
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] McLean Hosp, Boston, MA USA
[3] Yawkey Outpatient Care Ctr, Child & Adolescent Psychiat Serv, Boston, MA USA
[4] New York Presbyterian Hosp, Weill Cornell Med Ctr, Payne Whitney Clin, New York, NY USA
[5] Univ N Carolina, Sch Med, Carolina Inst Dev Disabil, Carrboro, NC USA
[6] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Yawkey Outpatient Care Ctr,Child & Adolescent Psy, Boston, MA USA
[7] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Lurie Ctr Autism, Lexington, MA USA
关键词
Antidepressants; atypical antipsychotics; autism; autism spectrum disorder; mood stabilizers; oxytocin; pervasive developmental disorders; psychopharmacology; stimulants; PERVASIVE DEVELOPMENTAL DISORDERS; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; CONTROLLED-RELEASE MELATONIN; ABERRANT BEHAVIOR CHECKLIST; GUANFACINE EXTENDED-RELEASE; N-ACETYL CYSTEINE; PLACEBO-CONTROLLED TRIAL; LONG-TERM SAFETY; OPEN-LABEL TRIAL; DOUBLE-BLIND;
D O I
10.1517/14656566.2016.1154536
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Individuals with autism spectrum disorder (ASD) commonly present for treatment of emotional and behavioral disturbances associated with ASD's "core" symptoms. Psychotropic medications are widely utilized in alleviating associated emotional and behavioral symptoms. Areas covered: Emotional and behavioral disturbances associated with ASD include irritability/severely disruptive behavior, which comprises the heaviest symptom burden; hyperactivity and other Attention-Deficit-Hyperactivity-Disorder (ADHD)-type symptoms; repetitive/stereotyped behaviors; and social withdrawal. Existing evidence for medications for each of these symptom clusters will be examined in this review. Expert opinion: Psychopharmacological treatment of core and associated symptoms in ASD is challenging, in large part because of the heterogeneity in the presentation of ASD. Furthermore, children and adolescents with ASD are more vulnerable to the side effects of psychopharmacological intervention than their age-matched, typically developing counterparts. Currently, risperidone and aripiprazole are the only medications that have been (relatively) reliably shown to help treat certain symptom clusters associated with ASD, namely severely disruptive behavior and hyperactivity. Recent studies have begun to look at medications with mechanisms that are novel in the treatment of ASD and that may address underlying pathophysiology and/or core symptoms such as glutamate-modulating agents. Overall, randomized, placebo-controlled studies of medications for the treatment of ASD are scarce.
引用
收藏
页码:937 / 952
页数:16
相关论文
共 155 条
[21]   Adverse effects of clomipramine [J].
Brasic, JR ;
Barnett, JY ;
Sheitman, BB ;
Tsaltas, MO .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1997, 36 (09) :1165-1166
[22]   CLOMIPRAMINE AMELIORATES ADVENTITIOUS MOVEMENTS AND COMPULSIONS IN PREPUBERTAL BOYS WITH AUTISTIC DISORDER AND SEVERE MENTAL-RETARDATION [J].
BRASIC, JR ;
BARNETT, JY ;
KAPLAN, D ;
SHEITMAN, BB ;
AISEMBERG, P ;
LAFARGUE, RT ;
KOWALIK, S ;
CLARK, A ;
TSALTAS, MO ;
YOUNG, JG .
NEUROLOGY, 1994, 44 (07) :1309-1312
[23]   Factor analysis of the aberrant behavior checklist in individuals with autism spectrum disorders [J].
Brinkley, Jason ;
Nations, Laura ;
Abramson, Ruth K. ;
Hall, Alicia ;
Wright, Harry H. ;
Gabriels, Robin ;
Gilbert, John R. ;
Pericak-Vance, Margaret A. O. ;
Cuccaro, Michael L. .
JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS, 2007, 37 (10) :1949-1959
[24]   Clomipramine in adults with pervasive developmental disorders: A prospective open-label investigation [J].
Brodkin, ES ;
McDougle, CJ ;
Naylor, ST ;
Cohen, DJ ;
Price, LH .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 1997, 7 (02) :109-121
[25]  
Buchsbaum MS, 2001, INT J NEUROPSYCHOPH, V4, P119, DOI 10.1017/S1461145701002280
[26]   Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: Results of an open-label study [J].
Buitelaar, JK ;
van der Gaag, RJ ;
van der Hoeven, J .
JOURNAL OF CLINICAL PSYCHIATRY, 1998, 59 (02) :56-59
[27]   CONTROLLED CROSSOVER STUDY OF TRIIODOTHYRONINE IN AUTISTIC-CHILDREN [J].
CAMPBELL, M ;
SMALL, AM ;
HOLLANDER, CS ;
KOREIN, J ;
COHEN, IL ;
KALMIJN, M ;
FERRIS, S .
JOURNAL OF AUTISM AND CHILDHOOD SCHIZOPHRENIA, 1978, 8 (04) :371-381
[28]   Clinical experience with Topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders [J].
Canitano, R .
BRAIN & DEVELOPMENT, 2005, 27 (03) :228-232
[29]  
Carter MJ, 2014, THER RECREAT J, V48, P275
[30]   Efficacy of Atomoxetine in Children With Severe Autistic Disorders and Symptoms of ADHD: An Open-Label Study [J].
Charnsil, Chawanun .
JOURNAL OF ATTENTION DISORDERS, 2011, 15 (08) :684-689